Easton Pharmaceuticals (Easton Pharmaceuticals) LT-Debt-to-Total-Asset : 0.29 (As of Sep. 2021)

View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Easton Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2021 was 0.29.

Easton Pharmaceuticals's long-term debt to total assets ratio declined from Dec. 2019 (0.49) to Sep. 2021 (0.29). It may suggest that Easton Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Easton Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Easton Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals LT-Debt-to-Total-Asset Chart

Easton Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec18

Dec19

Dec20

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.21

0.49

0.24

Easton Pharmaceuticals Quarterly Data
	Jun02	Sep02	Dec02	Mar03	Jun03	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec18	Dec19	Dec20	Mar21	Jun21	Sep21
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.49	0.24	0.28	0.28	0.29

Easton Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Easton Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (A: Dec. 2020 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2020 )	/	Total Assets (A: Dec. 2020 )
	=	2.482	/	10.192
	=

Easton Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2021 is calculated as

LT Debt to Total Assets (Q: Sep. 2021 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2021 )	/	Total Assets (Q: Sep. 2021 )
	=	2.837	/	9.968
	=

Easton Pharmaceuticals (OTCPK:EAPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Easton Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8

Website

http://www.eastonpharmaceuticalsinc.com

Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.